United Therapeutics (UTHR) Cash & Equivalents (2009 - 2026)

United Therapeutics (UTHR) has 18 years of Cash & Equivalents data on file, last reported at $1.3 billion in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents fell 32.64% year-over-year to $1.3 billion; the trailing twelve-month figure through Mar 2026 stood at $1.3 billion (down 32.64% YoY), and the FY2025 full-year result was $1.6 billion, down 8.25% from the prior year.
• Cash & Equivalents fell to $1.3 billion in Q1 2026, from $1.6 billion in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $1.9 billion in Q1 2025 to a low of $795.2 million in Q2 2022.
• A 5-year average of $1.3 billion and a median of $1.3 billion in 2024 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents soared 51.81% in 2025 and plunged 32.64% in 2026, its largest moves.
• Tracing UTHR's Cash & Equivalents over 5 years: stood at $961.2 million in 2022, then advanced by 25.65% to $1.2 billion in 2023, then surged by 40.53% to $1.7 billion in 2024, then slipped by 8.25% to $1.6 billion in 2025, then decreased by 17.82% to $1.3 billion in 2026.
• Business Quant data shows UTHR's Cash & Equivalents at $1.3 billion in Q1 2026, $1.6 billion in Q4 2025, and $1.3 billion in Q3 2025.